William J. Geese

• Matthew D. Hellmann14
• Hossein Borghaei10
• Julie R. Brahmer10
• Luis Paz‐Ares9
• Martin Reck9
• Scott Antonia7
• Chang Han6
• Leora Horn6
• Neal Ready6
• Prabhu Bhagavatheeswaran6
• Ben Creelan5
• David R. Spigel5
• Joseph D. Szustakowski5
• Kenneth J. O’Byrne5
• Naiyer A. Rizvi5
• Solange Peters5
• Enriqueta Felip4
• Martin Steins4
• Rosalyn A. Juergens4
• Scott Gettinger4
• Suresh S. Ramalingam4
• Xuemei Li4
• Adam Płużański3
• Ariella Sasson3

1. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

   著者: Robert L. Ferris, George R. Blumenschein, Jérôme Fayette, J. Guigay, A. Dimitrios Colevas, Lisa Licitra, Kevin J. Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even, Francis P. Worden, Nabil F. Saba, Lara Carmen Iglesias Docampo, Robert I. Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Manish Monga, Mark Lynch, William J. Geese, Justin Kopit, James W. Shaw, Maura L. Gillison - New England Journal of Medicine 2016 被引用: 5,078

2. Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

   著者: Matthew D. Hellmann, Luis Paz‐Ares, Reyes Bernabe Caro, Bogdan Żurawski, Sang‐We Kim, Enric Carcereny, Keunchil Park, Aurelia Alexandru, Lorena Lupinacci, Emmanuel de la Mora Jimenez, Hiroshi Sakai, István Albert, A. Vergnenègre, Solange Peters, Konstantinos Syrigos, Fabrice Barlési, Martin Reck, Hossein Borghaei, Julie R. Brahmer, Kenneth J. O’Byrne, William J. Geese, Prabhu Bhagavatheeswaran, Sridhar K. Rabindran, Ravi S. Kasinathan, Faith E. Nathan, Suresh S. Ramalingam - New England Journal of Medicine 2019 被引用: 2,835

3. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma

   著者: Ferdinandos Skoulidis, Michael E. Goldberg, Danielle Greenawalt, Matthew D. Hellmann, Mark M. Awad, Justin F. Gainor, Alexa B. Schrock, Ryan J. Hartmaier, Sally E. Trabucco, Laurie M. Gay, Siraj M. Ali, Julia A. Elvin, Gaurav Singal, Jeffrey S. Ross, David Fabrizio, Péter M. Szabó, Chang Han, Ariella Sasson, Sujaya Srinivasan, Stefan Kirov, Joseph D. Szustakowski, Patrik Vitazka, Robin Edwards, José A. Bufill, Neelesh Sharma, Sai‐Hong Ignatius Ou, Nir Peled, David R. Spigel, Hira Rizvi, Elizabeth Jiménez Aguilar, Brett W. Carter, Jeremy Erasmus, Darragh Halpenny, Andrew J. Plodkowski, Niamh M. Long, Mizuki Nishino, Warren L. Denning, Ana Galán‐Cobo, Haïfa Hamdi, Taghreed Hirz, Pan Tong, Jing Wang, Jaime Rodriguez‐Canales, Pamela Villalobos, Edwin R. Parra, Neda Kalhor, Lynette M. Sholl, Jennifer L. Sauter, Achim A. Jungbluth, Mari Mino–Kenudson, Roxana Azimi, Yasir Y. Elamin, Jianjun Zhang, Giulia C. Leonardi, Fei Jiang, Kwok‐Kin Wong, J. Jack Lee, Vassiliki A. Papadimitrakopoulou, Ignacio I. Wistuba, Vincent A. Miller, Garrett M. Frampton, Jedd D. Wolchok, Alice T. Shaw, Pasi A. Jänne, Philip J. Stephens, Charles M. Rudin, William J. Geese, Lee A. Albacker, John V. Heymach - Cancer Discovery 2018 被引用: 1,604

4. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

   著者: Matthew D. Hellmann, Tudor–Eliade Ciuleanu, Adam Płużański, Jong Seok Lee, Gregory A. Otterson, Clarisse Audigier-Valette, Elisa Minenza, Helena Linardou, Sjaak A. Burgers, Pamela Salman, Hossein Borghaei, Suresh S. Ramalingam, Julie R. Brahmer, Martin Reck, Kenneth J. O’Byrne, William J. Geese, George Green, Chang Han, Joseph D. Szustakowski, Prabhu Bhagavatheeswaran, Diane Healey, Yali Fu, Faith E. Nathan, Luis Paz‐Ares - New England Journal of Medicine 2018 被引用: 3,137

5. First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

   著者: David P. Carbone, Martin Reck, Luis Paz‐Ares, Ben Creelan, Leora Horn, Martin Steins, Enriqueta Felip, Michel M. van den Heuvel, Tudor–Eliade Ciuleanu, Firas Badin, Neal Ready, T. Jeroen N. Hiltermann, Suresh Nair, Rosalyn A. Juergens, Solange Peters, Elisa Minenza, John Wrangle, Delvys Rodríguez‐Abreu, Hossein Borghaei, George R. Blumenschein, Liza C. Villaruz, Libor Havel, Jana Krejčí, Jesus Corral Jaime, Han Chang, William J. Geese, Prabhu Bhagavatheeswaran, Allen C. Chen, Mark A. Socinski - New England Journal of Medicine 2017 被引用: 2,575

6. Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

   著者: Matthew D. Hellmann, Tavi Nathanson, Hira Rizvi, Ben Creelan, Francisco Sánchez-Vega, Arun Ahuja, Ai Ni, Jacki B. Novik, Levi Mangarin, Mohsen Abu-Akeel, Cailian Liu, Jennifer L. Sauter, Natasha Rekhtman, Eliza Chang, Margaret K. Callahan, Jamie E. Chaft, Martin H. Voss, Megan Tenet, Xuemei Li, Kelly L. Covello, Andrea Renninger, Patrik Vitazka, William J. Geese, Hossein Borghaei, Charles M. Rudin, Scott Antonia, Charles Swanton, Jeff Hammerbacher, Taha Merghoub, Nicholas McGranahan, Alexandra Snyder, Jedd D. Wolchok - Cancer Cell 2018 被引用: 1,175

7. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

   著者: Matthew D. Hellmann, Margaret K. Callahan, Mark M. Awad, Emiliano Calvo, Paolo A. Ascierto, Akin Atmaca, Naiyer A. Rizvi, Fred R. Hirsch, Giovanni Selvaggi, Joseph D. Szustakowski, Ariella Sasson, Ryan Golhar, Patrik Vitazka, Chang Han, William J. Geese, Scott Antonia - Cancer Cell 2018 被引用: 894

8. First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

   著者: Neal Ready, Matthew D. Hellmann, Mark M. Awad, Gregory A. Otterson, Martin Gutierrez, Justin F. Gainor, Hossein Borghaei, Jacques Jolivet, Leora Horn, Mihaela Mates, Julie R. Brahmer, Ian Rabinowitz, Pavan S. Reddy, Jason Chesney, James Michael Orcutt, David R. Spigel, Martin Reck, Kenneth J. O’Byrne, Luis Paz‐Ares, Wenhua Hu, Kim E. Zerba, Xuemei Li, Brian Lestini, William J. Geese, Joseph D. Szustakowski, George Green, Chang Han, Suresh S. Ramalingam - Journal of Clinical Oncology 2019 被引用: 596

9. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

   著者: Leora Horn, David R. Spigel, Everett E. Vokes, Esther Holgado, Neal Ready, Martin Steins, Elena Poddubskaya, Hossein Borghaei, Enriqueta Felip, Luis Paz‐Ares, Adam Płużański, Karen L. Reckamp, Marco Angelo Burgio, Martin Kohlhäeufl, David Waterhouse, Fabrice Barlési, Scott Antonia, Óscar Arrieta, Jérôme Fayette, Lucio Crinò, Naiyer A. Rizvi, Martin Reck, Matthew D. Hellmann, William J. Geese, Ang Li, Anne Blackwood‐Chirchir, Diane Healey, Julie R. Brahmer, Wilfried Eberhardt - Journal of Clinical Oncology 2017 被引用: 875

10. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

    著者: Matthew D. Hellmann, Naiyer A. Rizvi, Jonathan W. Goldman, Scott Gettinger, Hossein Borghaei, Julie R. Brahmer, Neal Ready, David E. Gerber, Laura Q.M. Chow, Rosalyn A. Juergens, Frances A. Shepherd, Scott A. Laurie, William J. Geese, Shruti Agrawal, Tina C. Young, Xuemei Li, Scott Antonia - The Lancet Oncology 2016 被引用: 961

11. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study

    著者: Scott Gettinger, Leora Horn, David M. Jackman, David R. Spigel, Scott Antonia, Matthew D. Hellmann, John D. Powderly, Rebecca S. Heist, Lecia V. Sequist, David C. Smith, Philip D. Leming, William J. Geese, Dennis J. Yoon, Ang Li, Julie R. Brahmer - Journal of Clinical Oncology 2018 被引用: 749

12. Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation

    著者: Charles M. Rudin, David Balli, W. Victoria Lai, Allison L. Richards, Evelyn M. Nguyen, Jacklynn V. Egger, Noura J. Choudhury, Triparna Sen, Andrew Chow, John T. Poirier, William J. Geese, Matthew D. Hellmann, Ann Forslund - Journal of Thoracic Oncology 2023 被引用: 87

13. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

    著者: E.E. Vokes, Neal Ready, Enriqueta Felip, Leora Horn, Marco Angelo Burgio, Scott Antonia, Osvaldo Arén Frontera, Scott Gettinger, Esther Holgado, David R. Spigel, David Waterhouse, Manuel Dómine, Marina Chiara Garassino, Laura Q.M. Chow, George R. Blumenschein, Fabrice Barlési, Bruno Coudert, Justin F. Gainor, Óscar Arrieta, Julie R. Brahmer, Charles Butts, Martin Steins, William J. Geese, A. Li, Diane Healey, Lucio Crinò - Annals of Oncology 2018 被引用: 469

14. Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC

    著者: Scott Gettinger, Matthew D. Hellmann, Laura Q.M. Chow, Hossein Borghaei, Scott Antonia, Julie R. Brahmer, Jonathan W. Goldman, David E. Gerber, Rosalyn A. Juergens, Frances A. Shepherd, Scott A. Laurie, Tina C. Young, Xuemei Li, William J. Geese, Naiyer A. Rizvi - Journal of Thoracic Oncology 2018 被引用: 179

15. Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung Cancer

    著者: Chang Han, Ariella Sasson, Sujaya Srinivasan, Ryan Golhar, Danielle Greenawalt, William J. Geese, George Green, Kim E. Zerba, Stefan Kirov, Joseph D. Szustakowski - Molecular Diagnosis & Therapy 2019 被引用: 55

16. 4O Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status

    著者: Suresh S. Ramalingam, David Balli, T-E. Ciuleanu, Adam Płużański, Jin Sun Lee, Michael Schenker, R. Bernabe Caro, K.H. Lee, Roberta Bartolucci, Clarisse Audigier-Valette, Matthew D. Hellmann, Luis Paz‐Ares, Martin Reck, Hossein Borghaei, Julie R. Brahmer, Kenneth J. O’Byrne, Phuong Tran, Thomas Spires, William J. Geese, Sachin Agrawal - Annals of Oncology 2021 被引用: 25

17. Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab

    著者: Tyler Alban, Nadeem Riaz, Prerana Bangalore Parthasarathy, Vladimir Makarov, Sviatoslav M. Kendall, Seong‐Keun Yoo, Rachna Shah, Nils Weinhold, Raghvendra M. Srivastava, Xiaoxiao Ma, Chirag Krishna, Juk Yee Mok, Wim J.E. van Esch, Edward B. Garon, Wallace Akerley, Ben Creelan, Nivedita Aanur, Diego Chowell, William J. Geese, Naiyer A. Rizvi, Timothy A. Chan - Nature Medicine 2024 被引用: 35

18. Biochemical Characterization and Tissue Distribution of Human SULT2B1

    著者: William J. Geese, Rebecca B. Raftogianis - Biochemical and Biophysical Research Communications 2001 被引用: 98

19. A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer

    著者: M. B. Mason, Óscar Lapuente-Santana, Anni S. Halkola, Wenyu Wang, Raghvendra Mall, Xu Xiao, Jacob M. Kaufman, Jingxin Fu, Jacob Pfeil, Jineta Banerjee, Verena Chung, Chang Han, Scott D. Chasalow, Hung‐Ying Lin, Rongrong Chai, Thomas Yu, Francesca Finotello, Tuomas Mirtti, Mikko I. Mäyränpää, Jie Bao, Emmy W. Verschuren, Eiman I. Ahmed, Michele Ceccarelli, Lance D. Miller, Gianni Monaco, Wouter Hendrickx, Shimaa Sherif, Lin Yang, Ming Tang, Shengqing Gu, Wubing Zhang, Yi Zhang, Zexian Zeng, Avinash Sahu, Yang Liu, Wenxian Yang, Davide Bedognetti, Jing Tang, Federica Eduati, Teemu D. Laajala, William J. Geese, Justin Guinney, Joseph D. Szustakowski, Benjamin G. Vincent, David P. Carbone - Journal of Translational Medicine 2024 被引用: 11

20. Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design

    著者: Nikhil I. Khushalani, Adi Diab, Paolo A. Ascierto, James Larkin, Shahneen Sandhu, Mario Sznol, Henry Koon, Anthony Jarkowski, Ming Zhou, Paul Statkevich, William J. Geese, Georgina V. Long - Future Oncology 2020 被引用: 28

21. Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients

    著者: Katharina König, Martin Peifer, Jana Fassunke, Michaela A. Ihle, Helen Künstlinger, Carina Heydt, Katrin Stamm, Frank Ueckeroth, Claudia Vollbrecht, Marc Bos, Masyar Gardizi, Matthias Scheffler, Lucia Nogová, Frauke Leenders, Kerstin Albus, Lydia Meder, Kerstin Becker, Alexandra Florin, Ursula Rommerscheidt‐Fuss, Janine Altmüller, Michael Kloth, Peter Nürnberg, Thomas Henkel, Sven-Ernö Bikár, Martin L. Sos, William J. Geese, Lewis C. Strauss, Yon‐Dschun Ko, Ulrich Gerigk, Margarete Odenthal, Thomas Zander, Jürgen Wolf, Sabine Merkelbach‐Bruse, Reinhard Buettner, Lukas C. Heukamp - Journal of Thoracic Oncology 2015 被引用: 94

22. Abstract CT082: Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage iv or recurrent non-small cell lung cancer: An exploratory analysis of CheckMate 026

    著者: Solange Peters, Ben Creelan, Matthew D. Hellmann, Mark A. Socinski, Martin Reck, Prabhu Bhagavatheeswaran, Han Chang, William J. Geese, Luis Paz‐Ares, David P. Carbone - Cancer Research 2017 被引用: 93

23. Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis

    著者: Solange Peters, S.S. Ramalingam, Luis Paz‐Ares, R. Bernabe Caro, Bogdan Żurawski, S.-W. Kim, Aurelia Alexandru, Lorena Lupinacci, Emmanuel de la Mora Jimenez, Hiroshi Sakai, István Albert, A. Vergnenègre, Martin Reck, Hossein Borghaei, Julie R. Brahmer, Kenneth J. O’Byrne, William J. Geese, Prabhu Bhagavatheeswaran, Faith E. Nathan, Matthew D. Hellmann - Annals of Oncology 2019 被引用: 33

24. NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC

    著者: Mark A. Socinski, Ben Creelan, Leora Horn, Martin Reck, Luis Paz‐Ares, Martin Steins, Enriqueta Felip, Michel M. van den Heuvel, Tudor–Eliade Ciuleanu, Firas Badin, Neal Ready, T. Jeroen N. Hiltermann, Suresh Nair, Rosalyn A. Juergens, Solange Peters, Elisa Minenza, William J. Geese, Prabhu Bhagavatheeswaran, A. Chen, David P. Carbone - Annals of Oncology 2016 被引用: 111

全 24 件を表示しました。